Xinhua Finance Frankfurt, March 7 (Reporter He Lili) Merck KGaAA, Germany, released its 2023 financial report on the 7th, saying that it expects Merck KGaA's earnings to return to moderate growth this year, mainly due to the gradual recovery of demand for special materials used in the manufacture of biotechnology drugs and semiconductors.
Merck KGaA said it expects a slight modest increase in organic sales in 2024, with healthcare as the main driver. For earnings before interest, taxes, depreciation and amortization (EBITDA), Merck also expects a slight organic increase, while foreign exchange factors are expected to lead to a 1% to 4% decline in earnings development.
Belén Garijo, Chairman and CEO of Merck KGaA, said on the same day: "In the medium term, our diversified businesses will continue to benefit from attractive market growth opportunities. We are now focused on a gradual return to growth in 2024 while defining a strategic roadmap to ensure Merck's long-term profitability and sustainable growth. ”
The financial report also shows that in 2023, Merck Group's net sales will decrease by 5% year-on-year6% to 209EBITDA of 9.3 billion euros decreased by 14.3 percent year-on-year2% to 587.9 billion euros.
Founded in 1668, Merck KGaA's businesses focus on innovative pharmaceuticals, life sciences and cutting-edge functional materials technologies.
Editor: Luo Hao.
Statement: Xinhua Finance is a national financial information platform undertaken by Xinhua News Agency. In any case, the information published on this platform does not constitute investment advice. If you have any questions, please contact customer service: 400-6123115